Show simple item record

dc.contributor.authorEchezarreta López, María Magdalena 
dc.contributor.authorCáceres Pérez, Amor R.
dc.contributor.authorEl Kory, Mohamed B.
dc.contributor.authorElhadj Malick, Kane
dc.contributor.authorSuárez González, Javier
dc.contributor.authorBetancor, Inés
dc.contributor.authorSoriano, Mabel
dc.contributor.authorSantoveña Estévez, Ana
dc.contributor.authorFariña, José B.
dc.contributor.otherIngeniería Química y Tecnología Farmacéutica
dc.date.accessioned2024-04-30T20:05:24Z
dc.date.available2024-04-30T20:05:24Z
dc.date.issued2021
dc.identifier.urihttp://riull.ull.es/xmlui/handle/915/37329
dc.description.abstractTuberculosis (TB) is one of the most severe and deadly infectious diseases in African region, where there is a high prevalence of multi-drug resistant tuberculosis (MDR-TB) too [1]. This resistant has increased in the recent years due to the commercialization of substandard and falsif ied medicines in low and middle income countries. The quality of the medicines may be affected in the whole steps of its lifecycle. In this sense, many medicines require specific conditions to ensure their quality during storage or shipping. In addition, climatic conditions of African countries are extremely harsh for many medicines, so packaging must be selected for environments with high temperature and humidity. Then, the detection of such poor-quality medicines it is essential to ensure an optimum treatment of TB disease and must be carried out by WHO-accredited reference laboratories [2]. In this way, the ISACAM project (www.isacam.eu) aims to establish a medicine quality assurance system in collaboration with the Laboratoire National de Contrôle de la Qualité des Médicaments (LNCQM) and achieve its qualification. Levofloxacin (LVFX) is one of the most widely used drugs to treat MDR-TB and its quality assurance is essential to cure the disease and prevent new resistance. The objective of this work was to evaluate the influence of storage conditions on the quality attributes of 3 LVFX medicines obtained from European and African supply-chain and compare the formulations through the dissolution profiles.en
dc.description.sponsorshipPrograma de Cooperación Interreg V-A MAC 2014-2020, ISACAM (MAC2/1.1a/219).
dc.format.mimetypeapplication/pdf
dc.relation.ispartofseriesRevista Española de Ciencias Farmacéuticas. 2021;2(2)
dc.rightsLicencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 Internacional)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es_ES
dc.titlePharmaceutical equivalence and stability study of levofloxacin tablets commercialized in Europe and Africaen
dc.typeinfo:eu-repo/semantics/article


Files in this item

This item appears in the following Collection(s)

Show simple item record

Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 Internacional)
Except where otherwise noted, this item's license is described as Licencia Creative Commons (Reconocimiento-No comercial-Sin obras derivadas 4.0 Internacional)